8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)

Anne Boerekamps, Thomas Vanwolleghem, Marc van der Valk, Guido E. van den Berk, Marjo van Kasteren, Dirk Posthouwer, Anthonius S. M. Dofferhoff, Bart van Hoek, Dewkoemar Ramsoekh, Jelle Koopsen, Janke Schinkel, Eric Florence, Joop E. Arends, Bart J. Rijnders*

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

Original languageEnglish
Pages (from-to)554-557
Number of pages4
JournalJournal of Hepatology
Volume70
Issue number3
DOIs
Publication statusPublished - Mar 2019

Keywords

  • HEPATITIS-C
  • LEDIPASVIR

Cite this

Boerekamps, A., Vanwolleghem, T., van der Valk, M., van den Berk, G. E., van Kasteren, M., Posthouwer, D., Dofferhoff, A. S. M., van Hoek, B., Ramsoekh, D., Koopsen, J., Schinkel, J., Florence, E., Arends, J. E., & Rijnders, B. J. (2019). 8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study). Journal of Hepatology, 70(3), 554-557. https://doi.org/10.1016/j.jhep.2018.10.032